CBDL Stock Overview
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CBD Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | -92.86% |
| 5 Year Change | -99.21% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CBDL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | -3.7% |
| 1Y | 0% | 11.4% | 20.2% |
Return vs Industry: CBDL underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: CBDL underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| CBDL volatility | |
|---|---|
| CBDL Average Weekly Movement | 8,070.6% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CBDL's share price has been volatile over the past 3 months.
Volatility Over Time: CBDL's weekly volatility has increased from 7862% to 8071% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 6 | Lisa Nelson | lbcbioscienceinc.com |
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. The company is based in Scottsdale, Arizona.
CBD Life Sciences Inc. Fundamentals Summary
| CBDL fundamental statistics | |
|---|---|
| Market cap | US$4.65m |
| Earnings (TTM) | -US$3.22m |
| Revenue (TTM) | US$138.19k |
0.0x
P/S Ratio0.0x
P/E RatioIs CBDL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBDL income statement (TTM) | |
|---|---|
| Revenue | US$138.19k |
| Cost of Revenue | US$73.52k |
| Gross Profit | US$64.67k |
| Other Expenses | US$3.28m |
| Earnings | -US$3.22m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CBDL perform over the long term?
See historical performance and comparison